IASLC - Immunotherapy In Driver - Positive NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez and two esteemed oncology colleagues discuss an evolving hot topic: the use of immune checkpoint inhibitors in the treatment of patie...
26 Heinä 202447min
Clinical Discussion in the Management of Early-Stage NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion on the management of early-stage disease, with an eye toward applying conclusions from trials such as the ADAU...
23 Heinä 202454min
LCC: The Management Of CNS Metastases In Driver Negative NSCLC
Description: Host Dr. Narjust Florez and two esteemed international clinicians discuss the unique characteristics of CNS metastases in patients with non-small cell lung cancer and small cell lung can...
16 Heinä 202447min
Lung Cancer Considered in Romanian
Continuing our series of podcasts in different world languages, this episode focuses on lung cancer research and treatment in Romanian. Host: Mihaela Aldea, MD PhD Thoracic Oncology and Precision M...
8 Heinä 202435min
The Importance of Waiting for Biomarker Results in NSCLC
Biomarkers are essential in lung cancer treatment, but they remain underutilized. In addition, clinicians and patients have to wait for those results before starting therapy. In this episode of Lung C...
2 Heinä 202450min
LCC In Italian--First-Line Treatment Options for EGFR Mutant NSCLC
This episode of Lung Cancer Considered discusses first-line treatment options for EGFR mutant NSCLC, in Italian. Guest: Dr. Jessica Menis is a thoracic medical oncologist with expertise in early-pha...
20 Kesä 202447min
FDA Approval Of Tarlartamab
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recently approved bispecific T-cell engager, tarlatamab, for small cell lung cancer. Guest: Dr. Anne-Marie Dingemans is a...
18 Kesä 202431min
ASCO 2024 Summary Part 2
In episode two summarizing important lung cancer data presented at ASCO 2024, Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu cover the phase III CROWN trial, ROS1 NSCLC with a nov...
14 Kesä 202449min
